Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 13/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5386005 | 0.86 | ALDH1A1 (0.57) | AGPAT2ALDH1A1KDM4EHSP90AA1HSP90AB1 | |
| SCHEMBL4280537 | 0.85 | HSP90AA1 (0.71) | AGPAT2ALDH1A1KDM4EHSP90AA1HSP90AB1 | |
| SCHEMBL14439010 | 0.81 | AGPAT2 (1.00) | AGPAT2ALDH1A1KDM4E | |
| SCHEMBL4286846 | 0.80 | ALDH1A1 (0.55) | AGPAT2ALDH1A1KDM4EHSP90AA1HSP90AB1 | |
| SCHEMBL4281980 | 0.79 | AGPAT2 (0.67) | AGPAT2ALDH1A1KDM4EHSP90AA1HSP90AB1 | |
| SCHEMBL5380261 | 0.78 | AGPAT2 (0.76) | AGPAT2ALDH1A1KDM4E | |
| SCHEMBL14439009 | 0.78 | AGPAT2 (1.00) | AGPAT2ALDH1A1KDM4E | |
| Ammonia Solution, Strong SCHEMBL5380432 | 0.77 | ALDH1A1 (0.55) | AGPAT2ALDH1A1KDM4EHSP90AA1HSP90AB1 | |
| SCHEMBL4281666 | 0.76 | AGPAT2 (0.67) | AGPAT2ALDH1A1KDM4ERECQLMEN1 | |
| SCHEMBL1915457 | 0.76 | ALDH1A1 (1.00) | AGPAT2ALDH1A1KDM4ERECQLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070178134-A1 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-7208507-B2 | Lysophosphatidic acid acyltransferase beta inhibitors; antiproliferative agents, treating tumors; [2-Chloro-6-(5-chloro-2-methoxy-phenyl)-pyridin-4-yl]-p-tolyl-amine for example | CELL THERAPEUTICS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050182102-A1 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2005-08-18 | — | — | US | disclosed |
| US-6875781-B2 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040198728-A1 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198728-A1 | Pyridines and uses thereof | LPCAT3, LPCAT1, PLAAT2 | AGPAT2 23/4885ALDH1A1 884/4885KDM4E 879/4885 |
| US-20070178134-A1 | Pyridines and uses thereof | LPCAT3, LPCAT1, PLAAT2 | AGPAT2 24/4885ALDH1A1 728/4885KDM4E 1025/4885 |
| US-20050182102-A1 | Pyridines and uses thereof | LPCAT3, LPCAT1, PLAAT2 | AGPAT2 24/4885ALDH1A1 728/4885KDM4E 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.